Dr Rebecca Bilton

Biography/ Background

Research Positions and Experience:

Post-doctoral Scientist (September 2005 - )/ Post-doctoral Fellow (July 2007-.

      Characterisation of the oxygen-sensor, FIH-1.
      Laboratory of Dr D. Peet, Molecular and Biomedical Sciences, The 
      University of Adelaide, Australia.

Funded by a Heart Foundation Grant, the ARC Special Research Centre for the Molecular Genetics of Development and a 3 year APDI Fellowship.

Post-doctoral Fellow (September 2003-2005).

      Expression and function of the acetyl-transferase ARD1, in angiogenesis
      and cancer.
      Laboratory of Dr J. Pouyssegur. Signalisation, Biologie du Developpement 
      et Cancer, CNRS-UMR 6543, Centre Antoine Lacassagne, Nice, France.

Funded by competitive fellowships from the World Health Organisation (1 year) and CNRS Poste Rouge -Foreign Research Associate Fellowship (1 year).

Post-doctoral position (2003, 6 months).

      Research into the biological function of the HIF-1a asparagine 
      hydroxylase, FIH1.
      Laboratory of Assoc. Prof. M. Whitelaw, Molecular Biosciences, The   
      University of Adelaide, Australia.

PhD candidature (1999- 2003).

      Studies into the Receptor-Mediated Induction of Hypoxia Inducible Factor
      1a 
      Biochemistry discipline, The University of Adelaide, Australia.

Funded with an APA and a CRC/CSIRO Top-up Scholarship for 4 years.

Research Assistant (1997-1999).

      Research on the identification, localisation and function of the Battens
      protein (CLN3p) and screening for putative Breast cancer tumour 
      suppressor genes.
      Laboratory of Prof. G. Sutherland. Department of Cytogenetics and 
      Molecular Biology, WCH, Adelaide, Australia.

Funded as part of an NHMRC grant.

Research Assistant (2 month placement, Feb-March 1998).

      Large-scale reverse genetic screen for C.elegans mutants.
      Nemapharm Biotech. Cambridge, Boston, USA.

Qualifications

PhD in Science (Biochemistry). 2003.
Studies into the Receptor-Mediated Induction of Hypoxia Inducible Factor 1a. Biochemistry, Molecular Biosciences, Adelaide University.

Bachelor of Biotechnology (Honours).
Biotechnology Department, Flinders University, SA. 1993-1996.

Research Interests

http://www.adelaide.edu.au/mbs/research/peet/

Publications

Wong YS, Farooq M, Bilton RL, Lee Y, Teo EW, Peet DJ, Ge R, Raghunath M. Prolyl/ asparaginyl hydroxylase inhibitors accelerate angiogenesis through HIF-1a: Novel applications of hydralazine, ciclopirox and pyridine-2, 4-dicarboxylate. Circ Res (submitted) Manuscript No: CIRCRESAHA/2007/157313. Impact Factor : 9.4

Bilton RL, Trottier E, Pouyssegur J and Brahimi-Horn MC. ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol. 2006 16(12):616-21. Impact Factor : 11.79 ; Citations (2)

Bilton RL, Mazure NM, Trottier E, Hattab M, Dery MA, Richard DE, Pouyssegur J and Brahimi-Horn MC. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1a and is not induced by hypoxia or HIF. J Biol Chem. 2005 280(35):31132-40. Impact Factor: 5.85; Citations (24)

Mazure NM, Brahimi-Horn MC, Berta MA, Bilton RL, Dayan F, Ginouves A, Berra E and Pouyssegur J. HIF-1: master and commander of the hypoxic world. Biochem Pharmacol. 2004. 68(6):971-80. Impact Factor: 3.61; Citations (30)

Bilton RL and Booker GW. The subtle side to Hypoxia Inducible Factor (HIF1a) regulation. Eur J Biochem. 2003. 270:1-8. Impact Factor: 3.16; Citations (42)

Settasatian C, Whitmore SA, Crawford J, Bilton RL, Cleton-Jansen, AM, Sutherland GR, Callen DF. Genomic structure and expression analysis of the spastic paraplegia gene, SPG7. Hum Genet. 1999 Jul-Aug; 105(1-2):139-44. Impact Factor: 4.33; Citations (13)

Kremmidiotis G, Lensink IL, Bilton RL, Woollatt E, Chataway TK, Sutherland GR, Callen DF.The Batten disease gene product (CLN3p) is a Golgi integral membrane protein. Hum Mol Genet. 1999 Mar; 8(3):523-31. Impact Factor: 7.76; Citations (31)

Entry last updated: Friday, 3 Aug 2007